BIIB vs. TECH: Biogen vs. Bio-Techne Stock Comparison

November 11, 2026

How do Biogen (BIIB) and Bio-Techne (TECH) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Biogen (BIIB) and Bio-Techne (TECH) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but BIIB is classified in Biotechnology while TECH is classified in Life Sciences Tools & Services.

Company profile comparison for Biogen (BIIB) and Bio-Techne (TECH)
Profile Item	BIIB	TECH
Name	Biogen Inc.	Bio-Techne Corp.
Country/Region	United States	United States
GICS Sector	Health Care	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Biotechnology	Life Sciences Tools & Services
GICS Sub-Industry	Biotechnology	Life Sciences Tools & Services
Market Capitalization	36.71 billion USD	11.43 billion USD
Currency	USD	USD
Exchange	Nasdaq	Nasdaq
Listing Date	September 17, 1991	February 9, 1989
Security Type	Common Stock	Common Stock

Price Performance

Cumulative Growth

BIIB

TECH

GSPC

Biogen (BIIB) vs. Bio-Techne (TECH), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for Biogen (BIIB) and Bio-Techne (TECH). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for Biogen (BIIB) and Bio-Techne (TECH). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Biogen (BIIB) and Bio-Techne (TECH)
Metric	BIIB	TECH
Total Return (1Y)	65.44%	27.56%
Total Return (3Y, Annualized)	4.62%	9.11%
Total Return (5Y, Annualized)	-0.96%	-9.91%

Risk Profile

Drawdown History

BIIB

TECH

GSPC

Biogen (BIIB) vs. Bio-Techne (TECH), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for Biogen (BIIB) and Bio-Techne (TECH). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Biogen (BIIB) and Bio-Techne (TECH)
Metric	BIIB	TECH
Volatility (1Y, Annualized)	34.58%	43.08%
Beta (5Y)	0.08	1.26
Max Drawdown (5Y)	-64.35%	-65.87%
Avg. Volume (3M)	1.05M	2.81M

Risk-Adjusted Performance

Risk-Return Positioning

BIIB and TECH are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Biogen (BIIB) and Bio-Techne (TECH)
Metric	BIIB	TECH
Sharpe Ratio (1Y)	1.77	0.54
Sortino Ratio (1Y)	2.77	0.82

Profitability

ROE (TTM)

Bio-Techne (TECH) at 8.33% sits in the top ROE quartile, while Biogen (BIIB) at 1.87% is closer to the peer norm — stronger capital efficiency for TECH.

BIIB

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.87%

Max: 109.18%
Q3: 6.23%
BIIB: 1.87%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

TECH

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.33%

Max: 109.18%
TECH: 8.33%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

Biogen (BIIB) vs. Bio-Techne (TECH): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Bio-Techne (TECH) at 14.00% retains a top-quartile share of revenue as profit, ahead of Biogen (BIIB) at 3.38%, which keeps about the industry-typical share.

BIIB

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.38%

Max: 18.05%
Q3: 4.78%
BIIB: 3.38%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

TECH

Pharmaceuticals, Biotechnology & Life Sciences industry group

14.00%

Max: 18.05%
TECH: 14.00%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

Biogen (BIIB) vs. Bio-Techne (TECH): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Biogen (BIIB) at 24.12% operates in the top operating margin quartile, ahead of Bio-Techne (TECH) at 12.21%, which runs around its industry’s norm.

BIIB

Pharmaceuticals, Biotechnology & Life Sciences industry group

24.12%

Max: 83.12%
BIIB: 24.12%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

TECH

Pharmaceuticals, Biotechnology & Life Sciences industry group

12.21%

Max: 83.12%
Q3: 14.77%
TECH: 12.21%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

Biogen (BIIB) vs. Bio-Techne (TECH): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Biogen (BIIB) and Bio-Techne (TECH)
Metric	BIIB	TECH
ROE (TTM)	1.87%	8.33%
ROA (TTM)	4.94%	6.38%
Net Margin (TTM)	3.38%	14.00%
Operating Margin (TTM)	24.12%	12.21%
Gross Margin (TTM)	75.77%	66.23%

Growth

Revenue Growth

Both Biogen (BIIB) at 2.22% and Bio-Techne (TECH) at -0.38% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Biogen (BIIB) vs. Bio-Techne (TECH): A comparison of their Revenue Growth across different time periods.

EPS Growth

Bio-Techne (TECH) at 152.17% sits in the top EPS growth quartile, while Biogen (BIIB) at -21.38% is closer to the peer norm — faster per-share earnings growth for TECH.

Biogen (BIIB) vs. Bio-Techne (TECH): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Biogen (BIIB) and Bio-Techne (TECH)
Metric	BIIB	TECH
Revenue Growth (YoY)	2.22%	-0.38%
Revenue Growth (3Y CAGR)	-0.94%	2.25%
EPS Growth (YoY)	-21.38%	152.17%
EPS Growth (3Y CAGR)	-25.04%	-12.97%

Financial Strength

Current Ratio (MRQ)

Both Biogen (BIIB) at 1.95 and Bio-Techne (TECH) at 2.28 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

BIIB

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.95

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
BIIB: 1.95
Min: 0.10

TECH

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.28

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
TECH: 2.28
Min: 0.10

Biogen (BIIB) vs. Bio-Techne (TECH): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Both Biogen (BIIB) at 0.41 and Bio-Techne (TECH) at 0.13 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

BIIB

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.41

Max: 1.42
Q3: 0.65
BIIB: 0.41
Median: 0.15
Q1: 0.02
Min: 0.00

TECH

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.13

Max: 1.42
Q3: 0.65
Median: 0.15
TECH: 0.13
Q1: 0.02
Min: 0.00

Biogen (BIIB) vs. Bio-Techne (TECH): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Biogen (BIIB) and Bio-Techne (TECH)
Metric	BIIB	TECH
Current Ratio (MRQ)	1.95	2.28
Debt / Equity (MRQ)	0.41	0.13
Net Debt / EBITDA	1.97	-0.20

Dividends

Dividend Yield (TTM)

Biogen (BIIB) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Bio-Techne (TECH) reports a yield of 0.44%, ranking against industry peers normally.

BIIB

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

BIIB: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

TECH

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.44%

TECH: 0.44%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Biogen (BIIB) vs. Bio-Techne (TECH): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Biogen (BIIB) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Bio-Techne (TECH) reports a payout of 27.59%, ranking against industry peers normally.

BIIB

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

BIIB: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

TECH

Pharmaceuticals, Biotechnology & Life Sciences industry group

27.59%

TECH: 27.59%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Biogen (BIIB) vs. Bio-Techne (TECH): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Biogen (BIIB) and Bio-Techne (TECH)
Metric	BIIB	TECH
Dividend Yield (TTM)	0.00%	0.44%
Dividend Payout Ratio (TTM)	0.00%	27.59%

Valuation

P/E Ratio (TTM)

Both look expensive on trailing earnings: Bio-Techne (TECH) at 62.74 sits in the richer P/E ratio quartile, and Biogen (BIIB) at 107.51 is richer still, above its industry range.

BIIB

Pharmaceuticals, Biotechnology & Life Sciences industry group

107.51

BIIB: 107.51
Max: 85.34
Q3: 43.46
Median: 26.69
Q1: 13.30
Min: 0.07

TECH

Pharmaceuticals, Biotechnology & Life Sciences industry group

62.74

Max: 85.34
TECH: 62.74
Q3: 43.46
Median: 26.69
Q1: 13.30
Min: 0.07

Biogen (BIIB) vs. Bio-Techne (TECH): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

On P/S ratio, both Biogen (BIIB) at 3.57 and Bio-Techne (TECH) at 9.31 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

BIIB

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.57

Max: 58.18
Q3: 25.77
Median: 7.30
BIIB: 3.57
Q1: 3.01
Min: 0.01

TECH

Pharmaceuticals, Biotechnology & Life Sciences industry group

9.31

Max: 58.18
Q3: 25.77
TECH: 9.31
Median: 7.30
Q1: 3.01
Min: 0.01

Biogen (BIIB) vs. Bio-Techne (TECH): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

On P/B ratio, both Biogen (BIIB) at 1.94 and Bio-Techne (TECH) at 5.28 are valued close to their industries’ norm against book — neither stands out from peers.

BIIB

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.94

Max: 13.53
Q3: 6.54
Median: 3.25
BIIB: 1.94
Q1: 1.69
Min: -5.59

TECH

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.28

Max: 13.53
Q3: 6.54
TECH: 5.28
Median: 3.25
Q1: 1.69
Min: -5.59

Biogen (BIIB) vs. Bio-Techne (TECH): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Biogen (BIIB) and Bio-Techne (TECH)
Metric	BIIB	TECH
P/E Ratio (TTM)	107.51	62.74
P/S Ratio (TTM)	3.57	9.31
P/B Ratio (MRQ)	1.94	5.28
Free Cash Flow Yield (TTM)	2.20%	2.39%